Premium
SGLT2 inhibitors and risk of genitourinary infections
Author(s) -
Chaplin Steve
Publication year - 2016
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1521
Subject(s) - dapagliflozin , empagliflozin , medicine , canagliflozin , genitourinary system , urinary system , type 2 diabetes , intensive care medicine , diabetes mellitus , population , endocrinology , environmental health
The SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin are now becoming established in the management of type 2 diabetes, but they are associated with an increased risk of genital and urinary tract infections, compounding the problem that people with diabetes are already at higher risk than the general population. This article examines the extent of these risks and how they may affect treatment adherence.